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Abstract
Background: Retroperitoneal sarcomas (RPS) include a heterogeneous group of rare malignant tumours, and
various treatment algorithms are still controversially discussed until today. The present study aimed to examine
postoperative and long-term outcomes after resection of primary RPS.
Patients and methods: Clinicopathological data of patients who underwent resection of primary RPS between
2005 and 2015 were assessed, and predictors for overall survival (OS) and disease-free survival (DFS) were identified.
Results: Sixty-one patients underwent resection for primary RPS. Postoperative morbidity and mortality rates were
31 and 3%, respectively. After a median follow-up time of 74 months, 5-year OS and DFS rates were 58 and 34%,
respectively. Histologic high grade (5-year OS: G1: 92% vs. G2: 54% vs. G3: 43%, P = 0.030) was significantly
associated with diminished OS in univariate and multivariate analyses. When assessing DFS, histologic high grade
(5-year DFS: G1: 63% vs. G2: 24% vs. G3: 22%, P = 0.013), positive surgical resection margins (5-year DFS: R0: 53% vs.
R1: 10% vs. R2: 0%, P = 0.014), and vascular involvement (5-year DFS: yes: 33% vs no: 39%, P = 0.001), were
significantly associated with inferior DFS in univariate and multivariate analyses.
Conclusions: High-grade tumours indicated poor OS, while vascular involvement, positive surgical resection
margins, and histologic grade are the most important predictors of DFS. Although multimodal treatment strategies
are progressively established, surgical resection remains the mainstay in the majority of patients with RPS, even in
cases with vascular involvement.
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Background
Soft tissue sarcomas (STS) are a heterogeneous group of
rare malignant tumours that can occur in almost any
anatomic region [1]. Whereas extremities are reported
to be more frequently involved, the incidence of a retro-
peritoneal origin is expected to be around 0.5 to 1 new
cases per 100.000 persons per year, representing ap-
proximately about 15% of all STS [2, 3]. Clinical symp-
toms are often nonspecific and usually a painless,
gradually enlarging neoplasm with a median size of 15
to 18 cm is one of the most common findings at diagno-
sis [4]. The potential to differentiate into many different
cell types results in a wide variety of histological entities.
The continual development of immunohistochemical
and molecular tools requires a continuous reassimilation
of classifications, and therefore the substantial compari-
son is difficult to make [5, 6]. The growth rate of retro-
peritoneal sarcomas (RPS) varies with the aggressiveness
of the tumour. Low-grade tumours may develop over a
long period, while high-grade tumours may occur with
early symptoms [7].
The retroperitoneum represents a sophisticated ana-
tomical space with multiple vital structures, and there-
fore RPS is associated with several therapeutic
challenges [8]. Especially the close relationship to vital
structures may significantly limit the ability to achieve
wide resection margins. Currently, various treatment al-
gorithms for patients with RPS have been controversially
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discussed [9]. Surgical resection involving wide margins,
with or without radiotherapy, offers the best chance for
a curative intended approach in the absence of meta-
static disease [10, 11]. Recent articles highlighted the
complexity and technical aspects of resection and
strongly advised early referral of these patients to highly
specialised centres [12, 13]. Despite recent advances in
diagnostic modalities, surgical techniques, and the im-
plementation of more aggressive strategies, RPS is still
prone to develop local recurrence approaching up to
50% in some series, even after an apparent complete re-
section and remains the primary cause of disease-related
death [14, 15]. While resection margins status, as well as
tumour grading, remain the most important predictors of
local recurrence and disease-free survival (DFS), evidence
on further prognostic parameters is still limited [8].
The objective of this study was to review our recent
experience with RPS and analyse postoperative and
long-term oncological outcomes. Besides, we aimed to
evaluate factors associated with overall survival (OS) and
DFS in this cohort and thus identify patients who may




Retrospective single-centre analysis conducted at the
Charité – Universitätsmedizin Berlin, Campus Virchow-
Klinikum in Berlin, Germany. Following permission
from the local institutional review board (EA1/361/14)
clinicopathological data of patients who underwent re-
section for primary RPS between 2005 and 2015 were
collected in a prospective database and further reviewed.
We excluded recurrent RPS from this analysis, due to di-
vergent management approaches and outcomes. An
interdisciplinary tumour board indicated all resections
and all patients obtained written informed consent.
Preoperative assessment
Standard preoperative clinical assessment included phys-
ical examination, serum laboratory testing, imaging stud-
ies, and an anaesthesia evaluation. Multiphase computed
tomography (CT) with contrast agents or magnetic res-
onance imaging (MRI) were computed to define the di-
mension and location of the sarcoma and to assess the
involvement of adherent structures. A multimodal thera-
peutic approach was individually formulated and sched-
uled by a multidisciplinary tumour board, which
consisted of surgeons, medical oncologists, specialised
radiation therapists, and radiologists, for every patient.
Due to the high recurrence rate and aggressive nature of
dedifferentiated liposarcoma, neoadjuvant chemotherapy
with/without radiation therapy was individually considered
for treatment, depending on the individual patient
presentation. Therefore, preoperative tissue diagnosis (89%)
of retroperitoneal liposarcoma included percutaneous bi-
opsy (image-guided core needle biopsy (CNB) or fine-
needle aspiration (FNA)) in order to facilitate an accurate
subtype-specific consideration for neoadjuvant therapy.
Surgical procedure
Perioperative antibiotics [Metronidazole 500 mg (i.v.)
and Cefuroxime 1 g intravenously (i.v.)] were routinely
given. All procedures were performed in an open surgi-
cal approach according to international standards at that
time [12]. A midline incision was the most common sur-
gical access facilitating best exposure as well as vascular
control. After laparotomy, a complete exploration of the
abdominal cavity evaluated local resectability of the sar-
coma and the extent of the resection. Especially the need
for multivisceral resection was carefully assessed based
on local findings such as vascular or other organ infiltra-
tion. The surgical procedure was adapted to the ana-
tomic region and intention to achieve radical tumour
removal as previously described [12]. Experienced sur-
geons performed all procedures at the study site.
Postoperative evaluation
All patients were administered and monitored at a spe-
cialised surgical intensive care unit for at least 1 day.
The Clavien-Dindo classification was used to grade post-
operative complications [16]. Complications within 90
days determined postoperative morbidity. Any in-
hospital death following resection defined postoperative
mortality. All resected specimens were histologically ex-
amined to identify the tumour entity and to evaluate
tumour-cell-free surgical margin. Definition of R0 in-
cluded neither macroscopic nor microscopic tumour
cells detectable in postoperative histology. Tumour sta-
ging based on the AJCC 8th, Ed. [17]. An interdisciplin-
ary tumour board recommended the use of additional
chemotherapy and radiotherapy on a case-by-case basis.
Our oncological outpatient clinic assessed long-term
follow-up. Besides, a detailed review of medical records,
as well as direct communication with the general practi-
tioners tracked patient survival or the documented day
of tumour recurrence or death. Fortunately, follow-up
data were available for all patients.
Statistical analysis
Unless otherwise specified, qualitative and quantitative
variables are constituted as medians (range) and num-
bers (frequencies). Postoperative morbidity, mortality,
OS, and DFS were defined as primary outcomes. Sur-
vival analysis was determined using the Kaplan-Meier
method, calculating OS from the date of resection to the
date of death or the last follow-up. DFS contained the
period from the date of resection to the date of first
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recurrence or last follow-up. Log-rank tests estimated
the significance of univariate analyses. To identify factors
associated with survival after resection of RPS, the fol-
lowing clinicopathological characteristics were recorded
and analyzed: patient sex, BMI, patient age at resection,
tobacco use, tumor entity, histologic grade, staging ac-
cording to the AJCC 8th Ed., chemotherapy, radiother-
apy, surgical resection margin, vascular involvement,
ASA physical status, and need for intraoperative transfu-
sion. Furthermore, a Cox multivariate regression model
was executed, including all variables associated with sur-
vival with P < 0.05 in univariate analysis. A P value below
0.05 was considered significant, and all statistical ana-
lyses were conducted using the SPSS software package,
version 24.0 (SPSS, Chicago, IL).
Results
Patient characteristics, postoperative morbidity, and
mortality
Between 2005 and 2015, 61 patients with primary RPS
underwent open resection at our institution. Table 1
summarises clinicopathological data of all patients. The
median age was 53 years (12–86), and 48% of patients
were male. Median BMI was 25 kg/m2 (16–42), and 15
(25%) patients acknowledged consistent tobacco usage.
Leiomyosarcoma and dedifferentiated liposarcoma had
the highest incidence with 19 (31%) and 14 (23%) pa-
tients, respectively. Twelve patients (20%) suffered from
well-differentiated liposarcoma, while undifferentiated
sarcoma, not otherwise specified, were identified in 13%
of all resected tumours. Pleomorphic liposarcoma, ma-
lignant peripheral nerve sheath tumours, were detected
in 5% of patients, respectively. Histologic grading
showed low-grade tumour tissue in 21 (34%) patients,
while intermediate grades and high grades were verified
in 11 (18%) and 29 (48%) cases, respectively. In terms of
the AJCC 8th Ed., the majority of patients (41%) were
classified to be Stage IIIB, while Stage IA, Stage IB, Stage
II, Stage IIIA and Stage IV were discovered in 3, 28, 7,
13, and 8%, respectively. Forty-nine patients (80%) re-
ceived no chemotherapy, while ten patients (16%) ob-
tained adjuvant chemotherapy. Two patients (3%)
received neoadjuvant chemotherapy. Based on the rec-
ommendations of an interdisciplinary tumour board, 44
patients (72%) did not require additional radiotherapy.
Four patients (7%) received neoadjuvant radiotherapy,
while 13 patients (21%) received adjuvant radiotherapy.
In 33 patients (54%) complete tumour removal was
achieved. The histological examination discovered per-
sistent tumour cells on the surgical resection margin in
18 patients (30%). In two patients (3%) only an R2 resec-
tion could be achieved, while in 8 patients (13%) histo-
logical examination did not state sufficient information
whether complete tumour resection with surgical
Table 1 Clinicopathologic characteristics of 61 patients who
underwent resection for primary retroperitoneal sarcoma
Characteristics All Patients
(N = 61)
Male sex, n (%) 29 (48)
Median age at resection (range), years 53 (12–86)
Median BMI (range) 25 (16–42)
Tobacco use, n (%) 15 (25)
Tumour entity, n (%)
Leiomyosarcoma 19 (31)
Liposarcoma, dedifferentiated 14 (23)
Liposarcoma, well-differentiated 12 (20)
Undifferentiated sarcoma, NOS 8 (13)
Liposarcoma, pleomorphic 3 (5)
Malignant Peripheral Nerve Sheath Tumors 3 (5)
Other 2 (3)
Histologic grade, n (%)
Low grade (G1) 21 (34)
Intermediate grade (G2) 11 (18)
High grade (G3) 29 (48)
AJCC 8th Ed., n (%)
Stage IA 2 (3)
Stage IB 17 (28)
Stage II 4 (7)
Stage IIIA 8 (13)
Stage IIIB 25 (41)













RX / Not stated 8 (13)
Vascular involvement, n (%) 17 (28)
Local recurrence, % 25 (41)
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margins microscopically negative for tumour cells was
successful. Seventeen patients (28%) revealed vascular
involvement. In this context, we planned vascular resec-
tion in 12 cases already preoperatively. In five cases, pre-
operative imaging studies underestimated the dimension
of RPS and diagnosis of vascular involvement, appeared
intraoperatively. The vena cava inferior was the most
common vessel involved. In eight cases, segmental resec-
tion required a reconstruction by PTFE prosthesis.
Within the remaining four cases, direct suture or patch
plastic occluded the area of resection. Five patients re-
vealed infiltration of the right renal vein. In all cases,
nephrectomy facilitated radical tumour removal. The
local recurrence rate of RPS was 41%. ASA physical sta-
tus included ASA I in 20% of patients, ASA II in 52% of
patients, ASA III in 23% of patients, and ASA IV in 5%
of patients. In 32 patients (52%) there was no necessity
for intraoperative red blood cell concentrate (RBCC)
transfusion during the surgical procedure.
Thirteen patients (21%) required up to two RBCCs
during the operation, while 26% of patients demanded
more than three RBCCs. Postoperative morbidity, ac-
cording to the Clavien-Dindo classification ≥3, was 31%,
and the 90-day mortality rate was 3%.
Long-term survival
After a median follow-up time of 74 months (2–131),
the median survival of patients who underwent resection
for RPS was 38 months. The 5-year OS rate was 58%
(Fig. 1), and 5-year DFS rate was 34% (Fig. 2). The re-
gion of resection was the most common site of tumour
recurrence.
Predictors of overall survival
Table 2 summarises the predictors of OS assessed by
univariate and multivariate analysis. Factors associated
with poor overall survival in the univariate analysis in-
cluded tumour entity (P = 0.018), and histologic tumour
grade (P = 0.015). In multivariate analysis, only histologic
tumor grade (hazard ratio [HR] 2.26, 95% CI 1.08–4.58,
P = 0.30) independently associated OS (Table 2).
Predictors of disease-free survival
Detailed predictors of DFS, based on the results of uni-
variate and multivariate analysis, are summarized in
Table 1 Clinicopathologic characteristics of 61 patients who




Need for intraoperative transfusions, n (%)
No red blood cell concentrate 32 (52)
1–2 red blood cell concentrate 13 (21)
≥ 3 red blood cell concentrate 16 (26)
90-day morbidity / Clavien-Dindo ≥3, n (%) 19 (31)
90-day Mortality, n (%) 2 (3)
BMI Body-mass-index, ASA American Society of Anesthesiologists, AJCC
American Joint
Committee on Cancer Staging Manual; NOS Not otherwise specified
















N = 61, 5-year overall survival rate: 58%
Fig. 1 Overall survival in 61 patients who underwent resection for primary RPS
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Table 3. In univariate analysis, factors associated with
poor DFS included patient age at resection (P = 0.006),
histologic tumor grade (P = 0.018), classification accord-
ing to the AJCC 8th Ed. (P = 0.004), surgical resection
margin (P = 0.047) and vascular involvement (P = 0.044).
In multivariate analysis, histologic grade (HR 2.07, 95%
CI 1.17–3.66, P = 0.013), positive surgical resection mar-
gins (HR 3.12, 95% 1.26–7.72, P = 0.014) and vascular in-
volvement ([HR] 5.04, 95% CI 1.90–13.33, P = 0.001),
were independently associated with DFS (Table 3). In
case of vascular involvement (28%), 5-year DFS was
33%, whereas no vascular involvement (72%) resulted in
5-year DFS rate of 39% (P = 0.044) (Fig. 3).
Discussion
This single-centre study examined the postoperative and
long-term results of patients treated with radical resec-
tion for primary RPS. In this study, 5-year OS and DFS
rates of 58 and 34%, respectively, were achieved, which
are following results from a previous analysis [4, 18, 19].
Previous studies have aimed to identify predictors for
improved OS in patients treated for RPS [20]. Factors re-
lated to the primary tumour such as tumour grade and
complete resection have been previously described to be
the most important predictors of local recurrence and
DFS [8].
On the other hand, further controversial studies did
not find any survival benefit related to factors such as
histological grade, vascular involvement, or tumour size
[21, 22]. The convincing benefit of radiotherapy and
chemotherapy has been a particular subject of current
debate and is still under evaluation [23]. Hence, given
data on prognostic factors for patients with RPS are het-
erogeneous, and we seek to define additional evidence
associated with survival in patients with RPS.
In a previous study on this subject, Nathan et al.
assessed 1365 patients within the framework of a Sur-
veillance, Epidemiology, and End Results (SEER) pro-
gram of patients undergoing resection for primary RPS
from 1988 to 2005 and reported similar patient charac-
teristics to those reported in our study [22]. Giuliano et
al. even assessed 2920 patients from a nationwide data-
base and found mainly the same distribution [20]. Lipo-
sarcoma and leiomyosarcoma remain the most common
histologic tumour entities. Likewise, the distribution of
histologic tumour grade in our analysis is similar. Our
median age at diagnosis of 53 years is slightly younger
than that reported by both authors, which may indicate
advancements in diagnostic modalities. We additionally
reported a 5-year OS of 58%, which is following the data
from Giuliano et al.
Tumour entity and histologic tumour grade of RPS
significantly impact on OS in our univariate analysis.
However, in multivariate analysis only histologic tumour
grade (G1: 92% vs G2: 54% vs G3: 43%, P = 0.015) inde-
pendently influenced OS. Equivalent to previous findings
it might reflect the more advanced nature of tumours
with high-grade transformation [8, 15, 18, 24]. Mean-
while, a 5-year OS rate of 58% indicates an improvement
compared to the 47% 5-year OS rate reported by Nathan



















N = 61, 5-year disease-free survival rate: 34%
Fig. 2 Disease-free survival in 61 patients who underwent resection for primary RPS
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Table 2 Univariate and multivariate analysis of clinicopathologic variables associated with overall survival in 61 patients who
underwent resection for primary retroperitoneal sarcoma






P Hazard Ratio (95% CI)
Sex .572
Male 29 (48) 45
Female 32 (52) 65
BMI (Body Mass Index) .483
< 25 28 (46) 65
≥25 33 (54) 52
Patient age at resection .157
≥ 60 years 21 (35) 40
18–59 years 38 (62) 68
< 18 years 2 (3) 100
Tobacco use .522
Yes 15 (25) 44
No 46 (75) 60
Tumour entity .018 NS
Leiomyosarcoma 19 (31) 71
Liposarcoma, dedifferentiated 14 (23) 32
Liposarcoma, well-differentiated 12 (20) 79
Undifferentiated sarcoma, NOS 8 (13) 31
Liposarcoma, pleomorphic 3 (5) 39
Malignant Peripheral Nerve Sheath Tumours 3 (5) 33
Other 3 (5) 78
Histologic grade, n (%) .015 .030 2.26 (1.08–4.58)
Low grade (G1) 21 (34) 92
Intermediate grade (G2) 11 (18) 54
High grade (G3) 29 (48) 43
AJCC 8th Ed., n (%) .511
Stage IA 2 (3) 94
Stage IB 17 (28) 88
Stage II 4 (7) 68
Stage IIIA 8 (13) 59
Stage IIIB 25 (41) 42
Stage IV 5 (8) 19
Chemotherapy n (%) .423
None 49 (80) 61
Neoadjuvant 2 (3) 51
Adjuvant 10 (16) 41
Radiotherapy .598
None 44 (72) 58
Neoadjuvant 4 (7) 67
Adjuvant 13 (21) 70
Surgical resection margin .186
R0 33 (54) 61
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et al. for SEER patients with RPS, which may be related to
the more aggressive operative treatment in recent decades
compared to that in the late 1980s and 1990s [20, 22]. While
both analyses from Nathan and Giuliano did not provide
DFS, we were able to report a 5-year DFS rate of 34%.
When addressing DFS, the univariate analysis in our
study identified patient age at resection, histological
grade, staging according to the AJCC 8th Ed., surgical
resection margin and vascular involvement as significant
predictive factors. In multivariate analysis, higher
tumour grading, positive resection margins, and vascular
involvement independently influenced disease-free
survival. Previous studies demonstrated that complete,
margin-free resection is essential for a potentially
curative-intended treatment for RPS [25]. Inability to
achieve completeness of tumour resection has a signifi-
cant adverse prognostic impact and correlates with high-
risk for disease-related death [26]. However, while
complete surgical resection is the most effective modal-
ity for the treatment of RPS, the role of R1 or R2 resec-
tion remains controversial. A study performed by
Shibata et al. determined clinical outcomes in patients
with incompletely resected RPS and noted that for pa-
tients with unresectable RPS, incomplete surgical resec-
tion provided prolongation of survival and successful
symptom palliation [27]. A combined series of 78 pa-
tients with RPS who did not undergo R0/R1 resection
demonstrated similar findings. In this bi-institutional
analysis, the median overall survival was approximately
20 months in the R2 resection cohort, versus 10 months
in the cohort who received supportive care or biopsy
only [28].
Furthermore, Strom and Mahvi performed a meta-
analysis on incomplete resection for RPS and found im-
proved survival at 5 years (44%) compared to survival in
patients having biopsy only (17%) [29]. It seems reason-
able to presume that tumour debulking or palliative re-
section can potentially postpone the development of a
critical tumour mass with subsequent symptoms. In our
analysis, two patients (3%) underwent R2 resection (both
dedifferentiated liposarcoma) and demonstrated survival
of 18 and 25months, respectively. Although the man-
agement of patients with unresectable RPS is involved
and the prognosis is generally poor, we believe that
unresectable RPS should not preclude operative inter-
vention per se. Consequently, following interdisciplinary
discussion in every case, we may recommend palliative
resection to alleviate significant symptoms and prolong
survival in highly selected patients.
To date, data regarding vascular involvement and
oncological outcomes after resection of RPS is still lim-
ited. Previous studies established the feasibility and
safety of en-bloc vascular resection for RPS and recom-
mended vascular resection and reconstruction to achieve
radical tumour removal when needed [30, 31]. However,
whether these complex procedures are associated with a
significant prolongation of survival is still unknown.
Poultsides et al. described vascular resection and
Table 2 Univariate and multivariate analysis of clinicopathologic variables associated with overall survival in 61 patients who
underwent resection for primary retroperitoneal sarcoma (Continued)






P Hazard Ratio (95% CI)
R1 18 (30) 45
R2 2 (3) 0
RX / Not stated 8 (13) 48
Vascular involvement .333
Yes 17 (28) 36
No 44 (72) 62
ASA physical status .066
I 12 (20) 90
II 32 (52) 63
III 14 (23) 56
IV 3 (5) 42
Need for intraoperative transfusions, % .303
No RBCC 32 (52) 56
1–2 RBCC 13 (21) 59
≥ 3 RBCC 16 (26) 30
* Cox regression multivariate analysis included all variables with P < 0.05 in univariate analysis. CI Confidence interval, NS Not significant, BMI Body-mass-index,
ASA American Society of Anesthesiologists, AJCC American Joint Committee on Cancer Staging Manual, NOS Not otherwise specified, RBCC Red blood cell concentrate
Entries with a p-value of < 0.05 in univariate or multivariate analysis are in boldface. A P value below 0.05 was considered significant.
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Table 3 Univariate and multivariate analysis of clinicopathologic variables associated with disease-free survival in 61 patients who
underwent resection for primary retroperitoneal sarcoma





P Hazard Ratio (95% CI)
Sex .649
Male 29 (48) 38
Female 32 (52) 32
BMI (Body Mass Index) .635
< 25 28 (46) 29
≥25 33 (54) 38
Patient age at resection .006 NS
≥ 60 years 21 (35) 16
18–59 years 38 (62) 47
< 18 years 2 (3) 50
Tobacco use .738
Yes 15 (25) 40
No 46 (75) 28
Tumour entity .311
Leiomyosarcoma 19 (31) 31
Liposarcoma, dedifferentiated 14 (23) 22
Liposarcoma, well-differentiated 12 (20) 33
Undifferentiated sarcoma, NOS 8 (13) 25
Liposarcoma, pleomorphic 3 (5) 39
Malignant Peripheral Nerve Sheath Tumours 3 (5) 29
Other 3 (5) 66
Histologic grade, n (%) .018 .013 2.07 (1.17–3.66)
Low grade (G1) 21 (34) 63
Intermediate grade (G2) 11 (18) 24
High grade (G3) 29 (48) 22
AJCC 8th Ed., n (%) .004 NS
Stage IA 2 (3) 85
Stage IB 17 (28) 71
Stage II 4 (7) 50
Stage IIIA 8 (13) 36
Stage IIIB 25 (41) 28
Stage IV 5 (8) 0
Chemotherapy n (%) .150
None 49 (80) 34
Neoadjuvant 2 (3) 50
Adjuvant 10 (16) 31
Radiotherapy .330
None 44 (72) 33
Neoadjuvant 4 (7) 50
Adjuvant 13 (21) 66
Surgical resection margin .047 .014 3.12 (1.26–7.72)
R0 33 (54) 53
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reconstruction during RPS resection with a significantly
increased perioperative morbidity, while the oncologic
outcome appeared equivalent to cases without signifi-
cant vascular involvement. The main finding was that
the need for vascular reconstruction almost doubled the
morbidity of these resections but was associated with a
comparable oncologic outcome (local recurrence and
overall survival). Our multivariate analysis identified
tumour entity and high tumour grade as independent
predictors of OS [32]. Our analysis partially confirms
Table 3 Univariate and multivariate analysis of clinicopathologic variables associated with disease-free survival in 61 patients who
underwent resection for primary retroperitoneal sarcoma (Continued)





P Hazard Ratio (95% CI)
R1 18 (30) 10
R2 2 (3) 0
RX / Not stated 8 (13) 44
Vascular involvement .044 .001 5.04 (1.90–13.33)
Yes 17 (28) 33
No 44 (72) 39
ASA physical status .659
I 12 (20) 48
II 32 (52) 36
III 14 (23) 23
IV 3 (5) 33
Need for intraoperative transfusions, % .899
No RBCC 32 (52) 38
1–2 RBCC 13 (21) 41
≥ 3 RBCC 16 (26) 37
* Cox regression multivariate analysis included all variables with P < 0.05 in univariate analysis. CI Confidence interval, NS Not significant, BMI Body-mass-index, ASA
American Society of Anesthesiologists, AJCC American Joint Committee on Cancer Staging Manual, NOS Not otherwise specified, RBCC Red blood cell concentrate
Entries with a p-value of < 0.05 in univariate or multivariate analysis are in boldface. A P value below 0.05 was considered significant.



















No vascular involvement, 72% of patients
N = 61, 5-year disease-free survival rate: 39%
Vascular involvement, 28% of patients
5-year disease-free survival rate: 33%
P = .044
Fig. 3 Disease-free Survival by vascular involvement. Patients without vascular involvement had significantly better disease-free survival than
those with vascular involvement (P = 0.044)
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these findings, demonstrating comparable OS between
patients with and without vascular involvement. How-
ever, in our study, patients with vascular involvement re-
curred earlier. The current study is to our knowledge
the first one to report on the association between vascu-
lar involvement and tumour recurrence, resulting in a 5-
year DFS rate of 72% in patients without vascular
involvement compared to 28% in those with proven vas-
cular infiltration. Vascular invasion may be the conse-
quence of biological aggressiveness of the tumour and
the need for vascular resection and reconstruction has
been examined for a variety of abdominal tumours. For
example, patients with pancreatic adenocarcinoma who
require portal vein resection have similar OS rates com-
pared to patients not requiring portal vein resection
[33]. Although vascular infiltration diminishes DFS in
patients with RPS, OS is not affected in our analysis.
Consequently, resection of RPS with vascular infiltration
can be performed in specialised centres and beneficially
prolong survival.
Chemotherapy and radiotherapy did not demonstrate a
significant impact on survival. While neoadjuvant therapy
is an established treatment for a variety of other tumour en-
tities, evidence on preoperative treatment for RPS is still
undetermined, and high-quality trials are needed [3, 34].
The limited efficacy of chemotherapy in RPS may be the re-
sult of a variety of reasons. The retroperitoneum represents
an ample anatomical space giving primary tumours the
ability to grow large before diagnosis, which then results in
less effective chemotherapy. Adjuvant radiotherapy is less
conventional due to gastrointestinal toxicities, and it is at
present not recommended as a standard treatment ap-
proach. Hence, preoperative radiation therapy is currently
the subject of a European randomised phase III study
(STRASS trial) [23, 35]. In summary, the rarity of the dis-
ease and lack of high quality randomised controlled data
highlights the demand for more international collaborations
to characterise the role of systemic therapy and radiother-
apy in the management of RPS in order to guide clinicians
in their preoperative and postoperative decision-making.
The present study is limited by common biases that
are mainly due to the retrospective character of this ana-
lysis. Furthermore, treatment regimens are still rather
heterogeneous. While extensive surgery remains the
mainstay of treatment in RPS, conflicting data on the
benefit of neoadjuvant and adjuvant therapies exist, and
thus interdisciplinary treatment plans are mainly based
on individual preference and expertise of the treating in-
stitution [36].
Conclusion
In conclusion, in our analysis of 61 patients, we found that
patient characteristics of RPS is similar to those of other
extensive studies, with liposarcoma and leiomyosarcoma
being the most common histologies. High-grade tumours
indicated poor OS, while histologic grade, positive resec-
tion margins, and vascular involvement are the most im-
portant predictors of DFS. Although preoperative and
postoperative radiotherapy and chemotherapy did not sig-
nificantly affect survival, procedures tailored to the indi-
vidual needs of our patients are the current advancement
of choice. While effective adjuvant treatment regimens are
continuously developed, surgical resection, even in cases
with vascular involvement should be individually
attempted in selected patients with RPS. Furthermore,
international collaborations are mandatory in order to en-
hance the management of RPS and guide clinicians in
their daily decision-making.
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